OncoPharm cover image

Lirafugratinib + LITESPARK011

OncoPharm

00:00

Lirafugratinib Targets FGFR2 Cholangiocarcinoma

John Bazar explains lirafugratinib’s approval for FGFR2-altered advanced cholangiocarcinoma and compares its selectivity with other FGFR inhibitors.

Play episode from 00:30
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app